MedTrace Logo

Study in Detection cfDNA for the Early-stage Diagnosis of Acute Rejection Post-renal Transplantation

NCT03759535 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-11-30

No results posted yet for this study

Summary

Acute rejection (AR) is still one of the major complications after kidney transplantation. The current diagnosis measure for AR is primarily pathological puncture test and hematuria biomarker detection, yet due to their inferior performance on timeliness, the allograft kidneys usually have been in severe conditions when the diagnoses take place. Donor derived cell free DNA (dd-cfDNA) is utilized as a measure for "liquid biopsy", it can predict acute rejection at very early periods, and it is easy to operate, with fewer invasive injuries, and can reflect related conditions in a timely manner, etc.. This study plans to utilize second-generation sequencing technology to systematically evaluate the abundance variations of nuclear genome and mitocondria derived dd-cfDNA in the kidney transplant recipients' blood and urine, thus it can assist in accumulating more proof for the clinical utilization of dd-cfDNA from different sources at the early stages of AR in evidence-based medicine, and lay foundation for the development of dd-cfDNA based early-stage rejection detection tools afterkidney transplantation surgery.

Conditions

  • Kidney Transplant Failure and Rejection

Interventions

DIAGNOSTIC_TEST

Acute rejection

Donor derived cell free DNA

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Zhang Ming, Doctor · RenJi Hospital

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2020-12-31
Completion
2021-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03759535 on ClinicalTrials.gov